```json
{
"content": [
{
"type": "paragraph",
"content": "The sciatica treatment market encompasses therapies and interventions addressing sciatic nerve pain, a condition affecting 15–40% of adults globally. With rising prevalence of degenerative spinal disorders and sedentary lifestyles, the market is a critical segment within the broader pain management industry. The global sciatica treatment market size was valued at approximately $2.1 billion in 2025, reflecting steady growth outlook as healthcare systems prioritize non-invasive and regenerative solutions. This market forecast underscores the industry expansion driven by technological innovation and evolving patient preferences."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["Drug Therapies", "Physical Therapy", "Injections", "Surgical Interventions"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[250, 265, 280, 295, 310, 325, 340, 355, 370, 385, 400, 415, 430, 445], // Drug Therapies
[120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185], // Physical Therapy
[80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145], // Injections
[50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115] // Surgical Interventions
]
}
},
{
"type": "paragraph",
"content": "The market is projected to grow at a CAGR of 6.8% from 2026 to 2033, with North America dominating the landscape due to advanced healthcare infrastructure and high treatment adoption. Asia-Pacific, however, is the fastest-growing region, fueled by rising awareness and economic development. Key forces shaping the industry include AI-driven diagnostics enhancing early intervention and regulatory tailwinds favoring minimally invasive procedures. Competitive intensity is rising as biopharma firms invest in regenerative medicine and gene therapy pipelines, signaling a shift toward personalized sciatica care."
}
]
}
```
